AIM: To describe current practices and philosophies of Australian ENT consultants and respiratory physicians in managing sinonasal disease in cystic fibrosis (CF). METHODOLOGY: An anonymous electronic survey was distributed to members of major Australian thoracic and otolaryngology societies, asking clinicians about their approaches to sinonasal management in CF. RESULTS: Sixty-eight clinicians responded, mostly otolaryngologists (85%); 70% had over 10 years of post-training experience. Most practised in New South Wales (31%), 79% worked across public and private settings, and 60% treated both adults and children. Over half saw only 1–10 CF patients annually. Almost all routinely enquired about sinonasal symptoms (97%), though just 19% used quality-of-life tools. For maximal medical therapy, nasal steroids (93%), isotonic saline irrigations (87%), and oral antibiotics (75%) were most strongly supported. Common symptoms prompting treatment were nasal obstruction (100%), facial pain or pressure (88%), and rhinorrhoea (79%). Surgery was most often considered for symptoms unresponsive to medical therapy. CT imaging was usually obtained after maximal medical treatment (51%) or before surgery (41%). Clinicians typically considered operative intervention between ages 6–10 (34%), although 29% reported that age did not limit surgery when indicated. Most respondents supported a role for modified endoscopic medial maxillectomy (69%), whereas fewer endorsed frontal sinus drill-out (29%). A large majority agreed that paranasal sinuses act as a bacterial reservoir (88%), and that aggressive medical or surgical therapy improves quality of life (96%), sinus symptoms (90%), and, to a lesser extent, pulmonary function (78%). CONCLUSION: Despite some variability, strong consensus exists regarding core therapies, indications for intervention, and the benefits of optimised management.